Finally. The months of waiting are over. (No, we aren’t talking about the Phillies’ attempt to dominate in the National League (it's ...

The biggest deal of the week, Daiichi’s purchase of the California biotech Plexxikon for $805 million upfront, prompted headlines elsewhere ...

Whiners, do-gooders and underdogs, go back to bed. Make yourselves some herbal tea. Go write in your journal or do a little scrapbooking. Ma...

By now you've noticed that we are fascinated by the potential for a pharmacogenomic marker--variability in the CYP2C19 genotype--to play...

Ah, awards season. Why should film critics have all the fun? And voting! It's not just for presidential elections. This year your IN VIV...

President-elect Barack Obama and his wife Michelle visited the White House this week: an event so closely tracked by the press that it was ...

New details about a pending Justice Department investigation of Ranbaxy recall some painful memories from veterans of the generic drug scand...

By now, you’ve probably heard that Ranbaxy and Daiichi have fallen in love —or at least entered a mutually binding financial agreement to th...

The temperature has been hot --and so has the deal-making. We counted at least 273 deals in the past five days. Not really. We actually sto...

Could Japanese pharmas be the Godzillas of the drug industry? With the money these outfits have been throwing around, they are certainly pu...

Another week, another big pharma reorganizes. This week comes news that Lilly's CEO John Lechleiter plans to reorganize several busine...